🔎 Trials Near Me

Home › Open-Angle Glaucoma › Florida

Pag-aaral pangklinika para sa Open-Angle Glaucoma sa Florida

6 pag-aaral para sa Open-Angle Glaucoma ang naghahanap ng mga kalahok sa mga site sa Florida.

Opisyal na teksto ng pag-aaral (English)

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

  • Brandon Eye Associates - Brandon /ID# 277074, Brandon
  • East Coast Institute for Research /ID# 280411, Jacksonville
Nagre-recruitPhase 3
Edad 45 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06822738

REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

  • Advanced Research, Deerfield Beach
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07675824

A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension

  • Advanced research, LLC, Boynton Beach
  • Advanced research, LLC, Weston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07661329

DSLT for Reducing Medication in Glaucoma

  • The Eye Institute of West Florida, Largo
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Abr 20, 2026 · NCT07390890

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

  • Bascom Palmer Eye Institute, Miami
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 5, 2026 · NCT07217678

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

  • Volusia Eye Associates, New Smyrna Beach
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 10, 2022 · NCT05401357

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.